

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Akerman et al.

Confirmation No.: 6643

Serial No.: 10/591,214

Group Art Unit No.: 1625

Filed: August 28, 2006

Examiner: Davis, Zinna Northington

For: COMPOUNDS, PHARMACEUTICAL  
COMPOSITIONS AND METHODS FOR USE IN  
TREATING METABOLIC DISORDERS

Docket No.: A-988-US-PCT

**RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT****Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Examiner Davis:

This is in reply to an Office Action mailed on September 4, 2009, imposing a restriction requirement in the above-captioned patent application. The shortened one-month statutory period for response to the Office Action expires on October 4, 2009. Accordingly, Applicants believe that this response is timely filed.

Applicants believe that no fees are due for this filing. However, should any fees be due, the Patent Office is hereby authorized to charge any additional fees required for this filing or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

In response to the restriction requirement, Applicants provisionally elect the claims, compounds, and compositions of Group I (claims 1-40) for examination without traverse. Applicants further elect the compound of Example 10.13, to begin prosecution.

**Remarks** begin on page 2 of this document.

**CERTIFICATE OF EFS-WEB TRANSMISSION**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted electronically through EFS-WEB to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on the date appearing below.

September 21, 2009  
Date

Jacqui Favar  
Name